Tagged With: PlantDerived
DEA Reclassifies Plant-Derived Marijuana Medicine To Schedule V
Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The US Food and Drug Administration had previously approved the product in June for the explicit treatment of two rare forms … Continue reading
FDA Approves Marketing Of Plant-Derived Marijuana Medicine
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The FDA’s decision was not unexpected, as the proprietary extract formulation — developed by … Continue reading
